Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population

Схожие документы

• Uptake and Usage Patterns of Biosimilar Infliximab in the Medicare Population
  по: Kozlowski, Steven, et al.
  Опубликовано: (2020)
• Influenza vaccination coverage estimates in the fee-for service Medicare beneficiary population 2006 – 2016: Using population-based administrative data to support a geographic based near real-time tool
  по: Shen, Angela K., et al.
  Опубликовано: (2018)
• Association between filgrastim biosimilar availability and changes in claim payments and Patient out-of-pocket costs for biologic Filgrastim Products
  по: Mouslim, Morgane C., et al.
  Опубликовано: (2020)
• Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product
  по: Halim, Liem Andhyk, et al.
  Опубликовано: (2018)
• Uptake of Infliximab Biosimilars Among the Medicare Population
  по: Chen, Alice J., et al.
  Опубликовано: (2020)